These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23750331)

  • 21. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
    Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
    Montero-Escribano P; Vila Silván C
    Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
    [No Abstract]   [Full Text] [Related]  

  • 23. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
    Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
    Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
    J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
    Stout SM; Cimino NM
    Drug Metab Rev; 2014 Feb; 46(1):86-95. PubMed ID: 24160757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.
    Herdegen T; Cascorbi I
    Dtsch Arztebl Int; 2023 Dec; 120(49):833-840. PubMed ID: 37874128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
    Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
    Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P; Trojano M
    Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic of two oral doses of a 1:20 THC:CBD
    Lyons C; McEwan K; Munn-Patterson M; Vuong S; Alcorn J; Chicoine A
    Front Vet Sci; 2024; 11():1352495. PubMed ID: 38585296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers.
    Hosseini A; McLachlan AJ; Lickliter JD
    Br J Clin Pharmacol; 2021 Apr; 87(4):2070-2077. PubMed ID: 33075170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
    Lehtinen T; Tolonen A; Turpeinen M; Uusitalo J; Vuorinen J; Lammintausta R; Pelkonen O; Scheinin M
    Biopharm Drug Dispos; 2013 Oct; 34(7):387-95. PubMed ID: 23852652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.
    Serpell M; Ratcliffe S; Hovorka J; Schofield M; Taylor L; Lauder H; Ehler E
    Eur J Pain; 2014 Aug; 18(7):999-1012. PubMed ID: 24420962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
    Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.